Su Ran Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth %
- Ebitda
- Net Worth -21.51%
- Total Assets %
About Su Ran Life Sciences
Su Ran Life Sciences Private Limited (SRLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 April 2018 (Six years and nine months 9 days old ). Its registered office is in Gurugram, Haryana, India.
The Company is engaged in the Research & Development Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kailash Rath, Suvendu Rath, Subasa Bishwal, and One other member serve as directors at the Company.
Company Details
-
Location
Gurugram, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U73200HR2018PTC073771
-
Company No.
073771
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Apr 2018
-
Date of AGM
29 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Su Ran Life Sciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subasa Bishwal
|
Director | 25-Apr-2018 | Current |
|
Kailash Rath
|
Director | 25-Apr-2018 | Current |
|
Suvendu Rath
|
Director | 25-Apr-2018 | Current |
|
Sudatta Dash
|
Director | 25-Apr-2018 | Current |
Financial Performance of Su Ran Life Sciences.
Su Ran Life Sciences Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 21.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Su Ran Life Sciences?
Unlock access to Su Ran Life Sciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Trasverse Biz Private LimitedSuvendu Rath is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Su Ran Life Sciences?
Unlock and access historical data on people associated with Su Ran Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Su Ran Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Su Ran Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.